Molecular Targets in Precision Chemoprevention of Colorectal Cancer: An Update from Pre-Clinical to Clinical Trials.

Adenomatous Polyposis Coli Protein / antagonists & inhibitors Animals Antineoplastic Agents / pharmacology Biomarkers, Tumor / genetics Colorectal Neoplasms / genetics Cyclooxygenase 2 / metabolism Cyclooxygenase 2 Inhibitors / therapeutic use Disease Models, Animal Fatty Acid Synthases / antagonists & inhibitors Humans Mice Molecular Targeted Therapy / methods Precision Medicine / methods
biomarkers colorectal cancer molecular targets precision prevention

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
17 Dec 2020
Historique:
received: 03 11 2020
revised: 07 12 2020
accepted: 13 12 2020
entrez: 22 12 2020
pubmed: 23 12 2020
medline: 16 3 2021
Statut: epublish

Résumé

Colorectal cancer (CRC) is one of the leading causes of cancer deaths worldwide. The initiation and progression of CRC is a multi-step process that proceeds via precursor lesions to carcinoma, with each stage characterized by its distinct molecular and tissue microenvironment changes. Precursor lesions of CRC, aberrant crypt foci, and adenoma exhibit drastic changes in genetic, transcriptomic, and proteomic profiles compared to normal tissue. The identification of these changes is essential and provides further validation as an initiator or promoter of CRC and, more so, as lesion-specific druggable molecular targets for the precision chemoprevention of CRC. Mutated/dysregulated signaling (

Identifiants

DOI: 10.3390/ijms21249609 PMID: 33348563 PMC: PMC7765969
pubmed: 33348563
pii: ijms21249609
doi: 10.3390/ijms21249609
pmc: PMC7765969
pii:
doi:

Substances chimiques

Adenomatous Polyposis Coli Protein 0
Antineoplastic Agents 0
Biomarkers, Tumor 0
Cyclooxygenase 2 Inhibitors 0
Cyclooxygenase 2 EC 1.14.99.1
Fatty Acid Synthases EC 2.3.1.85

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Division of Cancer Prevention, National Cancer Institute
ID : NIH/NCI R01CA 213987

Références

Int J Mol Sci. 2018 Aug 08;19(8):
pubmed: 30096840
Eur J Cancer. 2002 May;38(7):867-71
pubmed: 11978510
Cancer Res. 2007 Jan 15;67(2):445-9
pubmed: 17234750
Nat Rev Cancer. 2001 Oct;1(1):11-21
pubmed: 11900248
Cancer Res. 2012 Mar 15;72(6):1504-17
pubmed: 22266115
Biochem Biophys Res Commun. 2010 Aug 13;399(1):14-9
pubmed: 20633535
World J Gastroenterol. 2015 Jan 7;21(1):84-93
pubmed: 25574081
Int J Cancer. 2009 Jul 1;125(1):249-52
pubmed: 19358283
Int J Cancer. 2016 Mar 15;138(6):1482-93
pubmed: 26476372
J Natl Cancer Inst. 1994 Aug 3;86(15):1122-30
pubmed: 8028034
Clin Cancer Res. 2008 Oct 15;14(20):6525-30
pubmed: 18927292
Eur J Med Res. 2017 Oct 11;22(1):40
pubmed: 29020986
Oncogene. 2005 Nov 10;24(49):7320-6
pubmed: 16007128
PLoS One. 2015 May 29;10(5):e0127356
pubmed: 26024373
J Pathol. 1996 Mar;178(3):259-63
pubmed: 8778329
Cancer Epidemiol Biomarkers Prev. 2018 Jul;27(7):728-736
pubmed: 29769213
Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):502-8
pubmed: 16537708
Cancer Sci. 2004 Jun;95(6):475-80
pubmed: 15182426
Cancer Res. 2006 Jul 15;66(14):7370-7
pubmed: 16849589
FASEB J. 2015 Jun;29(6):2359-70
pubmed: 25713055
Int J Cancer. 2015 Mar 15;136(6):E488-95
pubmed: 25257656
Virchows Arch. 2016 Aug;469(2):125-34
pubmed: 27325016
Int J Colorectal Dis. 2010 Sep;25(9):1079-85
pubmed: 20549218
BMC Gastroenterol. 2014 Jan 02;14:1
pubmed: 24383454
J Natl Cancer Inst. 2012 Mar 7;104(5):415-20
pubmed: 22312135
Cancer Res. 2001 Dec 1;61(23):8357-60
pubmed: 11731407
Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):11859-11864
pubmed: 27708166
Clin Cancer Res. 2009 Oct 1;15(19):6208-16
pubmed: 19789310
Tumour Biol. 2014 Apr;35(4):3855-9
pubmed: 24430360
Mol Cancer Ther. 2003 Aug;2(8):815-23
pubmed: 12939472
J Clin Gastroenterol. 2018 May/Jun;52(5):431-436
pubmed: 28277374
Virchows Arch. 2009 Jun;454(6):667-76
pubmed: 19412621
Cell Signal. 2017 Nov;39:44-54
pubmed: 28757355
Carcinogenesis. 2002 Jan;23(1):201-5
pubmed: 11756242
BMC Cancer. 2013 Feb 01;13:48
pubmed: 23374535
Cancer Res. 2008 Sep 15;68(18):7670-5
pubmed: 18794156
Zhonghua Wei Chang Wai Ke Za Zhi. 2013 Sep;16(9):895-7
pubmed: 24062003
Gastroenterology. 2020 Jan;158(2):368-388
pubmed: 31563626
Chin J Cancer. 2011 Jul;30(7):450-62
pubmed: 21718591
Surg Endosc. 2018 Mar;32(3):1533-1539
pubmed: 28916945
Jpn J Clin Oncol. 1994 Jun;24(3):141-3
pubmed: 8007423
Cancer Res. 1995 Sep 1;55(17):3785-9
pubmed: 7641194
Cancer Sci. 2009 Dec;100(12):2283-91
pubmed: 19775287
Diagn Pathol. 2014 Apr 07;9:78
pubmed: 24708688
Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2413-21
pubmed: 25155760
J Carcinog. 2011 Mar 24;10:9
pubmed: 21483655
Carcinogenesis. 2007 Nov;28(11):2375-81
pubmed: 17557903
N Engl J Med. 2007 May 24;356(21):2131-42
pubmed: 17522398
Intest Res. 2017 Jan;15(1):75-82
pubmed: 28239316
J Gastroenterol Hepatol. 2007 Dec;22(12):2324-9
pubmed: 17559385
Sci Rep. 2016 Nov 14;6:37046
pubmed: 27841323
APMIS. 2010 Feb;118(2):115-24
pubmed: 20132175
Nat Rev Cancer. 2016 Mar;16(3):173-86
pubmed: 26868177
Cancer Prev Res (Phila). 2008 Jun;1(1):32-8
pubmed: 18841250
PLoS One. 2015 Mar 06;10(3):e0121402
pubmed: 25747113
Cancer Res. 1991 Sep 1;51(17):4528-34
pubmed: 1831401
Mol Cancer Ther. 2014 May;13(5):1206-16
pubmed: 24651526
J Gastroenterol. 2006 Mar;41(3):185-92
pubmed: 16699851
Oncotarget. 2018 May 15;9(37):24787-24800
pubmed: 29872506
Clin Cancer Res. 2016 Aug 15;22(16):4158-69
pubmed: 27528734
Cancer Res. 2000 Jan 15;60(2):293-7
pubmed: 10667579
J Biol Chem. 2003 May 23;278(21):19396-405
pubmed: 12626523
NPJ Precis Oncol. 2019 Jan 28;3:3
pubmed: 30701196
Fukushima J Med Sci. 2007 Jun;53(1):1-9
pubmed: 17957960
Gastroenterology. 1995 Feb;108(2):434-40
pubmed: 7835585
Curr Drug Targets. 2019;20(12):1217-1226
pubmed: 31215384
Gastroenterology. 2009 Mar;136(3):780-98
pubmed: 19263594
Tumour Biol. 2014 Aug;35(8):7929-34
pubmed: 24833093
Cancer Prev Res (Phila). 2010 May;3(5):597-603
pubmed: 20403997
Clin Colorectal Cancer. 2007 Sep;6(9):652-6
pubmed: 17945038
Biochim Biophys Acta. 2005 Nov 25;1756(2):83-96
pubmed: 16219426
Cell Prolif. 2016 Aug;49(4):448-59
pubmed: 27320813
Gastroenterology. 1996 Feb;110(2):375-82
pubmed: 8566583
J Cancer Res Clin Oncol. 2016 Jan;142(1):59-72
pubmed: 26109148
Mol Carcinog. 2015 Oct;54(10):986-98
pubmed: 24797894
Carcinogenesis. 2018 Mar 8;39(3):471-481
pubmed: 29361151
World J Gastroenterol. 2003 Jun;9(6):1246-50
pubmed: 12800233
J Cell Biochem. 2011 Sep;112(9):2490-501
pubmed: 21544861
Mol Cancer Res. 2019 Jan;17(1):140-152
pubmed: 30154249
Asian Pac J Cancer Prev. 2019 Jun 01;20(6):1675-1681
pubmed: 31244287
Cancer Treat Rev. 2010 Nov;36 Suppl 3:S56-61
pubmed: 21129611
J Natl Cancer Inst. 2014 Apr;106(4):dju016
pubmed: 24565956
J Lab Clin Med. 1993 Nov;122(5):518-23
pubmed: 8228569
Cancer Res. 2001 Sep 1;61(17):6307-12
pubmed: 11522616
Carcinogenesis. 2000 Jul;21(7):1319-27
pubmed: 10874009
Eur J Nutr. 2020 Apr;59(3):885-894
pubmed: 30919084
Cell Mol Gastroenterol Hepatol. 2018 May 24;6(3):257-276
pubmed: 30109253
Cancer Res. 2008 Nov 15;68(22):9331-7
pubmed: 19010907
Cancer Cell. 2016 Apr 11;29(4):587-601
pubmed: 27070705
Carcinogenesis. 1999 Sep;20(9):1709-13
pubmed: 10469614
Clin Cancer Res. 2015 Oct 1;21(19):4321-6
pubmed: 26106072
Prostaglandins Other Lipid Mediat. 2017 Sep;132:77-83
pubmed: 28089732
Nat Rev Gastroenterol Hepatol. 2016 Jun;13(6):352-61
pubmed: 27095653
Int J Cancer. 2009 Aug 1;125(3):541-7
pubmed: 19431205
Cancer Res. 2008 May 1;68(9):3251-9
pubmed: 18451151
JAMA. 2016 Jun 21;315(23):2564-2575
pubmed: 27304597
Biochim Biophys Acta. 2013 Aug;1836(1):80-9
pubmed: 23333833
Cancer Prev Res (Phila). 2011 Aug;4(8):1198-208
pubmed: 21576350
World J Gastroenterol. 2001 Jun;7(3):352-6
pubmed: 11819789
Cancer Res. 2003 Apr 15;63(8):1748-51
pubmed: 12702555
Int J Cancer. 2008 Jan 1;122(1):117-23
pubmed: 17847023
Gut. 2015 Sep;64(9):1419-25
pubmed: 25239119
J Natl Cancer Inst. 2012 May 2;104(9):709-16
pubmed: 22472308
Oncotarget. 2016 Jul 26;7(30):48335-48345
pubmed: 27340784
Carcinogenesis. 2014 Jul;35(7):1613-9
pubmed: 24632492
Am J Pathol. 2003 Mar;162(3):793-801
pubmed: 12598314
Cancer Prev Res (Phila). 2011 Nov;4(11):1895-902
pubmed: 21764859
Oncol Rep. 2014 Jan;31(1):335-41
pubmed: 24253664
Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6292-6297
pubmed: 30862734
Mol Oncol. 2013 Apr;7(2):178-89
pubmed: 23465602
Oncotarget. 2017 Mar 28;8(13):22175-22186
pubmed: 28077799
Arq Bras Cir Dig. 2017 Apr-Jun;30(2):114-117
pubmed: 29257846
Oncogene. 2012 Jun 14;31(24):2943-52
pubmed: 21986945
Sci Rep. 2018 Jan 12;8(1):671
pubmed: 29330435
Animal Model Exp Med. 2020 Mar 11;3(1):1-8
pubmed: 32318654
EBioMedicine. 2016 Aug;10:124-36
pubmed: 27448759
Cancer Med. 2019 Jun;8(6):3305-3313
pubmed: 31069997
Ann Clin Lab Sci. 2012 Fall;42(4):401-8
pubmed: 23090737
Acta Pharmacol Sin. 2008 Jan;29(1):1-20
pubmed: 18158862
J Agric Food Chem. 2012 Apr 11;60(14):3665-72
pubmed: 22439659
Int J Cancer. 2013 Sep 1;133(5):1259-65
pubmed: 23404247
Int J Cancer. 2014 Sep 15;135(6):1297-306
pubmed: 24510316
Biomed Pharmacother. 2019 Feb;110:473-481
pubmed: 30530050
Hum Pathol. 2019 Jul;89:44-50
pubmed: 31054900
Cancers (Basel). 2019 Sep 06;11(9):
pubmed: 31500168
Nitric Oxide. 2019 Feb 1;83:33-39
pubmed: 30590117
Adv Clin Chem. 2010;51:71-119
pubmed: 20857619
Free Radic Biol Med. 2003 Apr 15;34(8):955-68
pubmed: 12684081
Cancer Med. 2016 Jul;5(7):1599-606
pubmed: 27139420
Curr Drug Targets. 2008 May;9(5):369-74
pubmed: 18473764
Sci Rep. 2015 Nov 27;5:17376
pubmed: 26611322
J Korean Soc Coloproctol. 2012 Oct;28(5):253-8
pubmed: 23185705

Auteurs

Nagendra S Yarla (NS)

Center for Cancer Prevention and Drug Development, Medical Oncology, Department of Medicine, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.

Venkateshwar Madka (V)

Center for Cancer Prevention and Drug Development, Medical Oncology, Department of Medicine, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
ORCID: 0000-0002-8896-4095

Gopal Pathuri (G)

Center for Cancer Prevention and Drug Development, Medical Oncology, Department of Medicine, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.

Chinthalapally V Rao (CV)

Center for Cancer Prevention and Drug Development, Medical Oncology, Department of Medicine, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
VA Medical Center, Oklahoma City, OK 73104, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines suppresseurs de tumeurs › Protéine de la polypose adénomateuse colique › Molecular Targets in Precision Chemoprevention...
questionsmedicales.fr › Eucaryotes › Animaux › Molecular Targets in Precision Chemoprevention...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Molecular Targets in Precision Chemoprevention...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Molecular Targets in Precision Chemoprevention...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Maladies intestinales › Maladies du rectum › Tumeurs colorectales › Molecular Targets in Precision Chemoprevention...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Complexes multienzymatiques › Cyclooxygenase 2 › Molecular Targets in Precision Chemoprevention...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antirhumatismaux › Anti-inflammatoires non stéroïdiens › Inhibiteurs des cyclooxygénases › Inhibiteurs de la cyclooxygénase 2 › Molecular Targets in Precision Chemoprevention...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › Molecular Targets in Precision Chemoprevention...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Transferases › Acyltransferases › Acyl-carrier protein S-malonyltransferase › Fatty acid synthases › Molecular Targets in Precision Chemoprevention...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Molecular Targets in Precision Chemoprevention...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Molecular Targets in Precision Chemoprevention...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Thérapie moléculaire ciblée › Molecular Targets in Precision Chemoprevention...
questionsmedicales.fr › Professions de santé › Médecine › Médecine clinique › Médecine de précision › Molecular Targets in Precision Chemoprevention...